Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis
Zoledronate (Zol) is an anti-resorptive/tumoral agent used for the treatment of many cancers including spinal bone metastasis. High systemic administration of a single dose is now the standard clinical care, yet it has been associated with several side effects. Here, we aimed to evaluate the effects...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-08-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/8/8/1212 |
id |
doaj-174899d307f6439299dfa7806744adfa |
---|---|
record_format |
Article |
spelling |
doaj-174899d307f6439299dfa7806744adfa2020-11-24T22:20:48ZengMDPI AGJournal of Clinical Medicine2077-03832019-08-0188121210.3390/jcm8081212jcm8081212Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine MetastasisElie Akoury0Ana Sofia Ramirez Garcia Luna1Pouyan Ahangar2Xiaoya Gao3Pylyp Zolotarov4Michael H. Weber5Derek H. Rosenzweig6Department of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair & Recovery program, Montreal, QC H3G 1A4, CanadaDepartment of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair & Recovery program, Montreal, QC H3G 1A4, CanadaDepartment of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair & Recovery program, Montreal, QC H3G 1A4, CanadaDepartment of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair & Recovery program, Montreal, QC H3G 1A4, CanadaDepartment of Pathology, McGill University Health Centre, Montreal, QC H4A 3J1, CanadaDepartment of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair & Recovery program, Montreal, QC H3G 1A4, CanadaDepartment of Surgery, Division of Orthopaedic Surgery, McGill University and the Research Institute of the McGill University Health Centre, Injury Repair & Recovery program, Montreal, QC H3G 1A4, CanadaZoledronate (Zol) is an anti-resorptive/tumoral agent used for the treatment of many cancers including spinal bone metastasis. High systemic administration of a single dose is now the standard clinical care, yet it has been associated with several side effects. Here, we aimed to evaluate the effects of lower doses Zol on lung cancer and lung cancer-induced bone metastasis cells over a longer time period. Human lung cancer (HCC827) and three bone metastases secondary to lung cancer (BML1, BML3 and BML4) cells were treated with Zol at 1, 3 and 10 µM for 7 days and then assessed for cell proliferation, migration, invasion and apoptosis. Low Zol treatment significantly decreased cell proliferation (1, 3 and 10 µM), migration (3 and 10 µM) and invasion (10 µM) while increasing apoptosis (10 µM) in lung cancer and metastatic cells. Our data exploits the potential of using low doses Zol for longer treatment periods and reinforces this approach as a new therapeutic regimen to impede the development of metastatic bone cancer while limiting severe side effects following high doses of systemic drug treatment.https://www.mdpi.com/2077-0383/8/8/1212spinal bone metastasislung cancerzoledronatelow dose treatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Elie Akoury Ana Sofia Ramirez Garcia Luna Pouyan Ahangar Xiaoya Gao Pylyp Zolotarov Michael H. Weber Derek H. Rosenzweig |
spellingShingle |
Elie Akoury Ana Sofia Ramirez Garcia Luna Pouyan Ahangar Xiaoya Gao Pylyp Zolotarov Michael H. Weber Derek H. Rosenzweig Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis Journal of Clinical Medicine spinal bone metastasis lung cancer zoledronate low dose treatment |
author_facet |
Elie Akoury Ana Sofia Ramirez Garcia Luna Pouyan Ahangar Xiaoya Gao Pylyp Zolotarov Michael H. Weber Derek H. Rosenzweig |
author_sort |
Elie Akoury |
title |
Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis |
title_short |
Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis |
title_full |
Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis |
title_fullStr |
Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis |
title_full_unstemmed |
Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis |
title_sort |
anti-tumor effects of low dose zoledronate on lung cancer-induced spine metastasis |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2019-08-01 |
description |
Zoledronate (Zol) is an anti-resorptive/tumoral agent used for the treatment of many cancers including spinal bone metastasis. High systemic administration of a single dose is now the standard clinical care, yet it has been associated with several side effects. Here, we aimed to evaluate the effects of lower doses Zol on lung cancer and lung cancer-induced bone metastasis cells over a longer time period. Human lung cancer (HCC827) and three bone metastases secondary to lung cancer (BML1, BML3 and BML4) cells were treated with Zol at 1, 3 and 10 µM for 7 days and then assessed for cell proliferation, migration, invasion and apoptosis. Low Zol treatment significantly decreased cell proliferation (1, 3 and 10 µM), migration (3 and 10 µM) and invasion (10 µM) while increasing apoptosis (10 µM) in lung cancer and metastatic cells. Our data exploits the potential of using low doses Zol for longer treatment periods and reinforces this approach as a new therapeutic regimen to impede the development of metastatic bone cancer while limiting severe side effects following high doses of systemic drug treatment. |
topic |
spinal bone metastasis lung cancer zoledronate low dose treatment |
url |
https://www.mdpi.com/2077-0383/8/8/1212 |
work_keys_str_mv |
AT elieakoury antitumoreffectsoflowdosezoledronateonlungcancerinducedspinemetastasis AT anasofiaramirezgarcialuna antitumoreffectsoflowdosezoledronateonlungcancerinducedspinemetastasis AT pouyanahangar antitumoreffectsoflowdosezoledronateonlungcancerinducedspinemetastasis AT xiaoyagao antitumoreffectsoflowdosezoledronateonlungcancerinducedspinemetastasis AT pylypzolotarov antitumoreffectsoflowdosezoledronateonlungcancerinducedspinemetastasis AT michaelhweber antitumoreffectsoflowdosezoledronateonlungcancerinducedspinemetastasis AT derekhrosenzweig antitumoreffectsoflowdosezoledronateonlungcancerinducedspinemetastasis |
_version_ |
1725773851505197056 |